Artelo Biosciences’ (ARTL) Buy Rating Reaffirmed at D. Boral Capital

Artelo Biosciences (NASDAQ:ARTL)‘s stock had its “buy” rating reissued by D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They currently have a $6.00 price objective on the stock. D. Boral Capital’s price target would indicate a potential upside of 417.24% from the stock’s current price.

ARTL has been the subject of a number of other research reports. LADENBURG THALM/SH SH raised Artelo Biosciences to a “strong-buy” rating in a report on Wednesday, December 25th. EF Hutton Acquisition Co. I raised shares of Artelo Biosciences to a “strong-buy” rating in a report on Tuesday, October 1st. Finally, HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of Artelo Biosciences in a research report on Monday, December 9th.

Artelo Biosciences Stock Up 1.8 %

Shares of NASDAQ:ARTL opened at $1.16 on Tuesday. The company has a market capitalization of $3.74 million, a price-to-earnings ratio of -0.40 and a beta of 1.25. Artelo Biosciences has a 52 week low of $0.91 and a 52 week high of $1.75. The firm has a 50 day moving average of $1.09 and a 200 day moving average of $1.19.

Artelo Biosciences (NASDAQ:ARTL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.06. On average, sell-side analysts expect that Artelo Biosciences will post -2.62 EPS for the current year.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.